ALIMERA SCIENCES INC (ALIM) Stock Price, Quote, News and Overview
NASDAQ:ALIM - Nasdaq - US0162592028 - Common Stock - Currency: USD
ALIM Quote, Performance and Key Statistics
5.54
-0.01 (-0.18%)
The current stock price of ALIM is 5.54 USD. In the past month the price decreased by -0.72%. In the past year, price increased by 66.87%.
ALIM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ALIM
Company Profile
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. The company is headquartered in Alpharetta, Georgia and currently employs 159 full-time employees. The company went IPO on 2010-04-22. The company is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.
Company Info
ALIMERA SCIENCES INC
Ste 290, 6120 Windward Parkway
Alpharetta GEORGIA 30005 US
CEO: Richard S. Eiswirth Jr.
Employees: 159
Company Website: https://alimerasciences.com/
Phone: 16789905740
ALIMERA SCIENCES INC / ALIM FAQ
What is the stock price of ALIMERA SCIENCES INC today?
The current stock price of ALIM is 5.54 USD. The price decreased by -0.18% in the last trading session.
What is the ticker symbol for ALIMERA SCIENCES INC stock?
The exchange symbol of ALIMERA SCIENCES INC is ALIM and it is listed on the Nasdaq exchange.
On which exchange is ALIM stock listed?
ALIM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALIMERA SCIENCES INC stock?
9 analysts have analysed ALIM and the average price target is 5.78 USD. This implies a price increase of 4.33% is expected in the next year compared to the current price of 5.54. Check the ALIMERA SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALIMERA SCIENCES INC worth?
ALIMERA SCIENCES INC (ALIM) has a market capitalization of 301.27M USD. This makes ALIM a Small Cap stock.
How many employees does ALIMERA SCIENCES INC have?
ALIMERA SCIENCES INC (ALIM) currently has 159 employees.
What are the support and resistance levels for ALIMERA SCIENCES INC (ALIM) stock?
ALIMERA SCIENCES INC (ALIM) has a support level at 5.52 and a resistance level at 5.54. Check the full technical report for a detailed analysis of ALIM support and resistance levels.
Is ALIMERA SCIENCES INC (ALIM) expected to grow?
The Revenue of ALIMERA SCIENCES INC (ALIM) is expected to grow by 34.43% in the next year. Check the estimates tab for more information on the ALIM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ALIMERA SCIENCES INC (ALIM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALIM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALIM, evaluating the profitability, health, valuation and growth aspects
- ALIMERA SCIENCES INC (ALIM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALIMERA SCIENCES INC (ALIM) Sales and EPS estimates to see what analysts future expectations are.
- ALIMERA SCIENCES INC (ALIM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALIMERA SCIENCES INC (ALIM) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALIMERA SCIENCES INC (ALIM) Stock Chart to make your own analysis
- ALIMERA SCIENCES INC (ALIM) Latest news and press-releases to stay up to date.
Does ALIMERA SCIENCES INC (ALIM) stock pay dividends?
ALIM does not pay a dividend.
When does ALIMERA SCIENCES INC (ALIM) report earnings?
ALIMERA SCIENCES INC (ALIM) will report earnings on 2024-10-24, after the market close.
What is the Price/Earnings (PE) ratio of ALIMERA SCIENCES INC (ALIM)?
ALIMERA SCIENCES INC (ALIM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).
ALIM Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ALIM. When comparing the yearly performance of all stocks, ALIM is one of the better performing stocks in the market, outperforming 96.39% of all stocks.
ALIM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALIM. Both the profitability and financial health of ALIM have multiple concerns.
ALIM Financial Highlights
Over the last trailing twelve months ALIM reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 90.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.16% | ||
| ROE | -39.38% | ||
| Debt/Equity | 1.8 |
ALIM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 49% to ALIM. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 94.02% and a revenue growth 34.43% for ALIM